What is PolyPid?
PolyPid Ltd. (Nasdaq: PYPD) is a specialized biopharmaceutical firm dedicated to enhancing surgical outcomes through its proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology. This platform enables the precise, controlled, and prolonged release of active pharmaceutical ingredients directly at the surgical site, effectively mitigating risks such as post-operative infections. The company's lead candidate, D-PLEX100, is currently undergoing rigorous Phase 3 clinical trials, targeting the prevention of soft tissue and sternal bone infections. Beyond its surgical focus, PolyPid is exploring the potential of its OncoPLEX technology for the treatment of solid tumors, including glioblastoma, demonstrating a versatile application of its core drug delivery innovation.
How much funding has PolyPid raised?
PolyPid has raised a total of $139.9M across 8 funding rounds:
Series A
$2.2M
Series B
$10.9M
Series C
$8.3M
Series D
$22M
Private Equity
$5.3M
Series E
$50M
Debt
$14.5M
Stock/Share Issuance
$26.7M
Series A (2011): $2.2M, investors not publicly disclosed
Series B (2014): $10.9M, investors not publicly disclosed
Series C (2015): $8.3M supported by Financiere Saint James and GUIBOR
Series D (2016): $22M featuring Shavit Capital and Aurum Ventures Private
Private Equity (2016): $5.3M backed by Xenia Venture Capital
Series E (2019): $50M with participation from Undisclosed
Debt (2024): $14.5M, investors not publicly disclosed
Stock/Share Issuance (2025): $26.7M, investors not publicly disclosed
Key Investors in PolyPid
Xenia Venture Capital
A publicly traded investment firm based in Israel that specializes in high-tech and med-tech sectors, providing comprehensive support and strategic counseling to innovative life science companies.
Shavit Capital
An investment practice focused on late-stage financing for Israeli-related companies, utilizing equity mezzanine and bridge rounds to support firms with proven technologies and strong management teams.
Aurum Ventures Private
A specialized investment and asset management company that emphasizes technology-led innovation and high-quality asset development across various sectors.
What's next for PolyPid?
With the recent strategic investment, PolyPid is well-positioned to accelerate its clinical pipeline and transition toward commercialization. The focus remains on the successful completion of Phase 3 trials for D-PLEX100, which represents a significant value inflection point for the company. Furthermore, the firm is expected to allocate resources toward its preclinical oncology programs, potentially diversifying its therapeutic portfolio. As PolyPid navigates the complexities of late-stage clinical development, the company's ability to maintain its technological edge in controlled-release therapeutics will be paramount to achieving long-term market penetration and delivering value to stakeholders.
See full PolyPid company page
